» Articles » PMID: 39658862

Electronic Sepsis Screening Among Patients Admitted to Hospital Wards: A Stepped-Wedge Cluster Randomized Trial

Abstract

Importance: Sepsis screening is recommended among hospitalized patients but is supported by limited evidence of effectiveness.

Objective: To evaluate the effect of electronic sepsis screening, compared with no screening, on mortality among hospitalized ward patients.

Design, Setting, And Participants: In a stepped-wedge, cluster randomized trial at 5 hospitals in Saudi Arabia, 45 wards (clusters) were randomized into 9 sequences, 5 wards each, to have sepsis screening implemented at 2-month periods. The study was conducted between October 1, 2019, and July 31, 2021, with follow-up through October 29, 2021.

Intervention: An electronic alert, based on the quick Sequential Organ Failure Assessment score, was implemented in the electronic medical record in a silent mode that was activated to a revealed mode for sepsis screening.

Main Outcomes And Measures: The primary outcome was 90-day in-hospital mortality. There were 11 secondary outcomes, including code blue activation, vasopressor therapy, incident kidney replacement therapy, multidrug-resistant organisms, and Clostridioides difficile.

Results: Among 60 055 patients, 29 442 were in the screening group and 30 613 in the no screening group. They had a median age of 59 years (IQR, 39-68), and 30 596 were male (51.0%). Alerts occurred in 4299 of 29 442 patients (14.6%) in the screening group and 5394 of 30 613 (17.6%) in the no screening group. Within 12 hours of the alert, patients in the screening group were more likely to have serum lactate tested (adjusted relative risk [aRR], 1.30; 95% CI, 1.16-1.45) and intravenous fluid ordered (aRR, 2.17; 95% CI, 1.92-2.46) compared with those in the no screening group. In the primary outcome analysis, electronic screening resulted in lower 90-day in-hospital mortality (aRR, 0.85; 95% CI, 0.77-0.93; P < .001). Screening reduced vasopressor therapy and multidrug-resistant organisms but increased code blue activation, incident kidney replacement therapy, and C difficile.

Conclusions And Relevance: Among hospitalized ward patients, electronic sepsis screening compared with no screening resulted in significantly lower in-hospital 90-day mortality.

Trial Registration: ClinicalTrials.gov Identifier: NCT04078594.

References
1.
Wang C, Xu R, Zeng Y, Zhao Y, Hu X . A comparison of qSOFA, SIRS and NEWS in predicting the accuracy of mortality in patients with suspected sepsis: A meta-analysis. PLoS One. 2022; 17(4):e0266755. PMC: 9012380. DOI: 10.1371/journal.pone.0266755. View

2.
Schorr C, Odden A, Evans L, Escobar G, Gandhi S, Townsend S . Implementation of a multicenter performance improvement program for early detection and treatment of severe sepsis in general medical-surgical wards. J Hosp Med. 2016; 11 Suppl 1:S32-S39. DOI: 10.1002/jhm.2656. View

3.
Al-Dorzi H, Aldawood A, AlMatrood A, Burrows V, Naidu B, Alchin J . Managing critical care during COVID-19 pandemic: The experience of an ICU of a tertiary care hospital. J Infect Public Health. 2021; 14(11):1635-1641. PMC: 8481117. DOI: 10.1016/j.jiph.2021.09.018. View

4.
Luther M, Timbrook T, Caffrey A, Dosa D, Lodise T, LaPlante K . Vancomycin Plus Piperacillin-Tazobactam and Acute Kidney Injury in Adults: A Systematic Review and Meta-Analysis. Crit Care Med. 2017; 46(1):12-20. DOI: 10.1097/CCM.0000000000002769. View

5.
Shakeshaft A, Doran C, Petrie D, Breen C, Havard A, Abudeen A . The effectiveness of community action in reducing risky alcohol consumption and harm: a cluster randomised controlled trial. PLoS Med. 2014; 11(3):e1001617. PMC: 3949675. DOI: 10.1371/journal.pmed.1001617. View